HOME > News Releases 2022 > Countermeasures Against and the Status of the Spreading of the Coronavirus Disease (COVID-19)(Updated)

Text Size


Countermeasures Against and the Status of the Spreading of the Coronavirus Disease (COVID-19)(Updated)

Apr. 22, 2022

We would like to express our deepest sympathies to those infected or otherwise affected by the coronavirus disease (COVID-19). We also sincerely hope that those people who have lost their lives rest in peace.

ESPEC CORP. is working to prevent the spread of the coronavirus disease (COVID-19) in accordance with the policies and requests of national and local governments so as to protect the safety of our customers, business partners, and regional communities as well as the safety of our employees and their families. The Company's response and status are as follows.

■Status of ESPEC CORP.

(1) The Fukuchiyama Plant (Kyoto) is conducting manufacturing while implementing infection prevention countermeasures.

(2) Sales and service facilities across Japan are operating while utilizing telecommuting and staggered work hours.

(3) To ensure that they can be used safely by our customers, our laboratory testing service facilities across Japan are continuing operations while thoroughly implementing infection prevention measures.

(4) Customer Support Desk We have hours that the Customer Support Desk is open to 10:00 a.m. to 5:00 p.m.

Customer Support Desk: https://www.espec.co.jp/english/inquiry/customer-oversea.php

■ Employee vaccination

To help prevent the spread of infections, we are dedicated to making it easy for employees who wish to be vaccinated to do so. Work on the day of and after vaccination will be treated as follows to allow employees to be vaccinated with greater peace of mind.

  • Employees can use paid leave if receiving the vaccine on a weekday.
  • If an employee has an adverse reaction to the vaccine, any necessary days off will be treated as special leave per employment regulations.

Contact Details:

Corporate Communication Department ESPEC CORP.

TEL:06-6358-4744 FAX:06-6358-4795

Notices Regarding the Novel Coronavirus